Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: Role of B7-H1 and IDO

Immunology and Cell Biology

Volumn 88, Issue 8, 2010, Pages 795-806

  Tipnis, Shabari ^a   Viswanathan, Chandra ^a   Majumdar, Anish S ^a  

^a RELIANCE LIFE SCIENCES PVT LTD   (India)

Author keywords

B7 H1; indoleamine 2,3 dioxygenase; mesenchymal stem cells; T cell immunosuppression; umbilical cord

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; N METHYLTRYPTOPHAN; PROGRAMMED DEATH 1 LIGAND 1;

ALLOGENEIC RESTRICTION; ALLOTRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; CELL CONTACT; CELL CULTURE; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL; MONOCYTE; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UMBILICAL CORD;

ANTIBODIES, BLOCKING; ANTIGENS, CD; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; FETAL BLOOD; HLA-DR ANTIGENS; HUMANS; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MESENCHYMAL STEM CELLS; T-LYMPHOCYTES, REGULATORY; TRYPTOPHAN;

EID: 78649333063     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.47     Document Type: Article

References (54)

1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.
2. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
3. Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM. Identification of mesenchymal stem/progenitor cells in human first trimester fetal blood liver and bone marrow. Blood 2001; 98: 2396-2402.
4. Flynn A, Barry F, O'Brien T. Umbilical cord blood derived mesenchymal stem cells: an overview. Cytotherapy 2007; 9: 717-726.
5. McElreavey KD, Irvine AI, Ennis KT, McLean WH. Isolation, culture and characterization of fibroblast-like cells derived from the Wharton's jelly portion of human umbilical cord. Biochem Soc Trans 1991; 19: 29S.
6. Verfaillie CM, Schwartz R, Reyes M, Jian Y. Unexpected potential of adult stem cells. Ann NY Acad Sci 2003; 996: 230-234.
7. Shetty P, Ravindran G, Sarang S, Thakur A, Rao H, Viswanathan C. Clinical grade mesenchymal stem cells transdifferentiated under xenofree conditions alleviates motor deficiency in rat model of Parkinson's disease. Cell Biol Int 2009; 33: 830-838.
8. Weiss ML, Medichetty S, Bledsoe AR, Rachakatla RS, Choi M, Merchav S et al. Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells 2006; 24: 781-792.
9. Chapel A, Bertho JM, Bensidhoum M, Fouillard L, Young RG, Frick J et al. Mesench-ymal stem cell home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 2003; 5: 1028-1038.
10. Pereira RF, Halford KW, O'Hara MD, Leeper DB, Sokolov BP, Pollard MD et al. Cultured adherent cells from marrow can serve as long lasting precursor cells for bone, cartilage and lung in irradiated mice. Proc Natl Acad Sci USA 1995; 92: 4857-4861.
11. Osiris Therapeutics. Clinical trials for prochymal by osiris therapeutics for autologous and allogeneic bone marrow transplantation, clinicaltrials.gov.
12. Maitra B, Szekely E, Gjini K, Laughlin MJ, Dennis J, Haynesworth SE et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T cell activation. Bone Marrow Transplant 2004; 33: 597-604.
13. Kiyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance and suppression. J Biomed Sci 2005; 12: 47-57.
14. Patel SA, Sherman L, Munoz J, Rameshwar P. Immunological properties of mesench-ymal stem cells and clinical implications. Arch Immunol Ther Exp 2008; 56: 1-8.
15. Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. Review. J Inflamm 2005; 2: 8-18.
16. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features and potential for homing. Stem Cells 2007; 25: 2739-2749.
17. Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of programmed death 1 pathway. Eur J Immunol 2005; 35: 1482-1490.
18. Sheng H, Wang Y, Jin Y, Zhang Q, Zhang Y, Wang L et al. A critical role of IFNg priming MSC-mediated suppression of T cell proliferation through up regulation of B7-H1. Cell Res 2008; 18: 846-857.
19. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822.
20. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F et al. Human mesenchymal stem cells modulate B cell functions. Blood 2006; 107: 367-372.
21. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74-85.
22. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immonol 2006; 36: 2566-2573.
23. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T cell responses by indoleamine 2, 3-dioxygenase mediated tryptophan degradation. Blood 2004; 103: 4619-4621.
24. Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH. Cells expressing indoleamine-2,3, dioxygenase inhibit T cell responses. J Immunol 2002; 168: 3771-3776.
25. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroid resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-1586.
26. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034.
27. + T cell proliferation by augmenting IFN-g-induced nitric oxide production. J Immunol 2005; 175: 1586-1592.
28. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchy-mal stem cells from bone marrow, umbilical cord blood or adipose tissue. Stem Cells 2006; 24: 1294-1301.
29. Yoo KH, Jang IK, Lee MW, Kim HE, Yang MS, Eom Y et al. Comparison of immuno-modulatory properties of mesenchymal stem cells from adult tissues. Cell Immunol 2009; 259: 150-156.
30. Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ et al. Mesenchymal stem cells in Wharton's jelly of the human umbilical cord. Stem Cells 2004; 22: 1330-1337.
31. Seshreddy K, Troyer D, Weiss ML. Method to isolate mesenchymal like cells from Wharton's jelly of umbilical cord. Methods Cell Biol 2008; 86, 101-119.
32. Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoietic supportive function and other potentials. Hematologica 2006; 91: 1017-1026.
33. Shetty P, Cooper K, Viswanathan C. Comparison of proliferative and multilineage differentiation potentials of cord matrix cord blood and bone marrow derived mesen-chymal stem cells. Asian J Transf Sci 2010; 4: 14-24.
34. Rond SL, Gonzalez A, Gonzalez AS, Corosella ED, Freiss NR. Indoleamine 2, 3 dioxygenase and human leukocyte antigen-G inhibit the T cell alloproliferative response through two independent pathways. Immunology 2005; 116: 297-307.
35. Xiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte derived dendritic cells. Blood 2005; 105: 4120-4126.
36. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit differentiation and function of both CD34+ and monocyte derived dendritic cells. J Immunol 2006; 177: 2080-2087.
37. Li L, Baroja M, Majumdar A, Chadwick K, Rouleau A, Gallacher L et al. Human embryonic stem cells possess immune privileged properties. Stem Cells 2004; 22: 448-456.
38. Weiss ML, Anderson C, Medichetty S, Seshareddy KB, Weiss RJ, Werff IV et al. Immune properties of human umbilical cord Wharton's jelly derived cells. Stem Cells 2008; 26: 1-9.
39. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T cell responses by indoleamine 2, 3-dioxygenase mediated tryptophan degradation. Blood 2004; 103: 4619-4621.
40. Glinnie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105: 2821-2827.
41. Nicola MD, Stella CC, Magni M, Milanesi M, Longoni PD. Human bone marrow stromal cells suppress T cell lymphocyte proliferation induced by cellular or non specific mitogenic stimuli. Blood 2002; 99: 3838-3843.
42. Oh W, Kim DS, Yang YS, Lee JK. Immunological properties of umbilical cord blood derived mesenchymal stromal cells. Cell Immunol 2008; 251: 116-123 e-pub ahead of print 20 May 2008.
43. Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C et al. Immunomodu-latory effect of human adipose tissue derived adult stem cell: comparison with bone marrow mesenchymal stem cells. Br J Haematol 2005; 129: 118-129.
44. Secco M, Zucconi E, Vieira NM, Fogaça LL, Cerqueira A, Carvalho MD et al. Multipotent stem cells from umbilical cord: cord is richer than blood!. Stem Cells 2008; 26: 146-150.
45. Troyer DL, Weiss ML. Concise review: Wharton's jelly derived cells are a primitive stromal cell population. Stem Cells 2008; 26: 591-599.
46. Nasef A, Ashammakhi N, Fouillard L. Immunomodulatory effect of mesenchymal stromal cells: possible mechanisms. Regen Med 2008; 4: 1-16.
47. Ennis J, Gotherstrom C, LeBlanc K, Davies J. In vitro immunologic properties of human umbilical cord perivascular cells. Cytotherapy 2008; 10: 174-181.
48. Stagg J, Pommey S, Eliopoulos N, Galipeau J. Interferon\{gamma}\ stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 2006; 107: 2570-2577.
49. Dazzi F, Berg FM. Mesenchymal stem cells for graft-versus-host-disease: close encounters with T cells. Eur J Immunol 2008; 38: 1-4.
50. Rasmusson I. Immune modulation by mesenchymal stem cells. Exp Cell Res 2006; 12: 2169-2179.
51. Nasef A, Chapel A, Mazurier C. Identification of IL-10 and TGF-b transcripts involved in the inhibition of T lymphocyte proliferation during cell contact with human mesench-ymal stem cells. Gene Expr 2007; 13: 217-226.
52. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or non-specific mitogenic stimuli. Blood 2002; 99: 3838-3843.
53. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007; 149: 353-363.
54. Popma SH, Krasinskas AM, McLean AD, Szeto WY, Kreisel D, Moore JS et al. Immune monitoring in xenotransplantation: the multiparameter flow cytometric mixed lymphocyte culture assay. Cytometry 2000; 42: 277-283.